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T-cell receptors: Feeling out the complex
Eduardo A. Padlan* and David H. Margulies†
Recent crystallographic studies show that the T-cell
receptor has a largely immunoglobulin-like structure and
binds to MHC–peptide complexes through loops from
paired Va and Vb domains that focus on the central
amino acids of the MHC-bound peptide, and to bacterial
superantigens via peripheral aspects of the Vb domain.
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Since the first descriptions of genetic control of immune
responsiveness in the early 1970s [1–3], immunologists
have followed a sinuous trail leading from phenomenology
to mechanism. Following the initial success in determin-
ing high-resolution crystal structures of fragments of a T-
cell receptor b chain [4] and Va domain [5], several
laboratories have now reported structures of T-cell recep-
tors alone or bound to antigen-presenting major histocom-
patibility complex (MHC) molecules or superantigens
[6–8]. These structures offer a deeper understanding of
the initial events that trigger T-cell activation, and should
prompt the formulation of new hypotheses concerning
signal transduction in T cells.
The T-cell receptor is a multichain molecular complex
with a binding specificity that allows it to sense structural
variations among complexes between class I or class II
MHC molecules and antigenic peptides, expressed on the
surface of antigen-presenting cells. The specificity of the
T-cell receptor lies in the clonally-restricted structure of
the ab (or possibly gd) chains, which form a combining
site that recognizes a particular subset of peptide–MHC
complexes. When a T-cell receptor recognizes its unique
cognate peptide–MHC complex, the cell that bears it is
activated through an intricate cascade of phosphorylation,
molecular recruitment and second-messenger generation.
As a result of activation, the T cell produces soluble medi-
ators, such as lymphokines, modulates the cell-surface
expression of its receptor and accessory molecules, and
controls a finely tuned immunological response that
includes antibody production, attraction of inflammatory
cells and direct effector functions. 
A clone of T cells, characterized by a unique ab T-cell
receptor, is generated by the somatic rearrangement of T-
cell receptor a and b chain genes, along with the timed
Figure 1
(b)

(c)

VH
VL
CH1
C H2
CH3
CL
Fab
Fc
V α Vβ
Cα
Cβζ
CD3T-cell receptor Immunoglobulin
ε εγδ
© 1997 Current Biology
The domain structures of T-cell receptors and immunoglobulins. (a) A
space-filling representation of the tight elbow bend between Vb and
Cb of a T-cell receptor b chain [4]. At the top, the CDR1 is green,
CDR2 is violet, CDR3 is yellow and HV4 is red; the Cb insertion is light
green. (b) A schematic diagram of an entire T-cell receptor complex.
(c) A schematic diagram of an immunoglubulin G molecule. (The
space-filling structure in (a) is reproduced with permission from [4]).
The copyright holder has not
given permission to reproduce
this figure in an electronic
format.
expression of coreceptor molecules CD4 or CD8, which
define T cells that recognize class II or class I MHC mole-
cules, respectively. This occurs in the thymus, where the
cells are positively selected for expression of receptors
with at least a low level of affinity for self MHC mole-
cules, but also negatively selected to eliminate cells
bearing receptors that have a high affinity for self MHC
molecules. Although it has been particularly difficult to
assess quantitatively the differences in affinity of T-cell
receptors that determine the positive versus negative
selection of the cells bearing them, measurements made
in several different systems suggest that the window of
affinity that allows this discrimination is narrow [9,10].
Once a particular clone of T cells has been established, the
mature T cell is poised to identify foreign, dysregulated
self or neo-tumor antigens on a class of cells generically
termed antigen-presenting cells. Our accumulating knowl-
edge of MHC and now T-cell receptor structure urges us
to think of antigen–MHC complexes as minor structural
variants on a major theme. These structural variations
result from the selection of different peptides from the
antigen-presenting cell by its class I or class II MHC mole-
cules. Thus, via either the endogenous (class I) or endo-
cytic (class II) pathway, MHC molecules first capture and
then display peptides representative of the cell in which
they are expressed or foreign antigens they encounter.
T-cell receptor structure 
The three-dimensional structures of various T-cell recep-
tor fragments and of several receptor–ligand complexes
have now been determined by X-ray crystallography. The
first structures to be determined were those of fragments:
the extracellular portion of an isolated b chain (Fig. 1) [4]
and an isolated Va domain [5]. More recently, the struc-
ture of the entire extracellular portion of a murine ab T-
cell receptor has been revealed [6]. Further, views have
been obtained of this T-cell receptor (Fig. 2) [6] and of a
human ab T-cell receptor [7] in ternary complexes with
their cognate peptide–MHC complexes. 
In addition to their cognate peptide–MHC complex, some
T-cell receptors also bind tightly to the ‘superantigens’
produced by pathogenic bacteria such as Staphylococcus.
Superantigens are so-called because of their ability to bind
to whole classes of T-cell receptors, and thus elicit very
powerful immune responses. To provide insight into this
biologically curious and medically important phenome-
non, the structure of the complex between a T-cell recep-
tor b chain and a superantigen has also been determined
[8]. These structural analyses [4–8] confirm the general
predictions based on amino-acid sequence and structural
arguments [11–14] as well as those based on mutational
and functional evidence [15,16]. The details of these pre-
dictions and models are now moot, as the new structures
resolve issues of precise orientation and molecular contact.
As predicted, the individual T-cell receptor domains
exhibit the fold characteristic of immunoglobulin
domains. The variable domains of both a and b chains of
the T-cell receptor (see Figs 1,2) resemble antibody vari-
able domains, and their mode of association is reminiscent
of antibody VL–VH interactions. The constant domains of
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Figure 2
A backbone representation of a complex between a T-cell receptor and
a peptide–MHC ligand [6]. The T-cell receptor (2C) is at the top and
the peptide–MHC complex below (with the peptide in green; b2M
refers to b2-microglobulin). In the T-cell receptor representation, Va
CDR1 and CDR2 are magenta, Va HV4 is white, Vb CDR1 and CDR2
are blue, Vb HV4 is orange, and both CDR3s are green. (Reproduced
with permission from [6].)
The copyright holder has not
given permission to reproduce
this figure in an electronic
format.
T-cell receptors resemble antibody constant domains, up
to a point (see below), and the relative disposition of the
constant and variable T-cell receptor modules is not
unlike that found in antibody ‘Fabs’ (VLCL/VHCH1 units).
The major loops connecting b strands in the amino-termi-
nal part of the molecule form the complementarity-deter-
mining regions (CDRs) which are disposed in essentially
the same manner as that found in antibodies. 
The T-cell receptor Vb domain closely resembles an
immunoglobulin variable domain (Fig. 1); it is more like a
VL than a VH domain in the framework regions, and in the
CDRs it has features found in both VL and VH domains.
CDR loop length is a useful way to compare such struc-
tures. Vb CDR1 is quite short — ten or eleven residues
long [17], comparable to the shortest VL CDR1. Vb
CDR2 is longer than VL CDR2, and is more similar to the
VH CDR2. Vb CDR3 is quite variable in length, ranging
from eight to eighteen amino acids [17], so Vb more
closely resembles VH in this region (though immunoglob-
ulin l light chains sometimes have a long CDR3). Inter-
estingly, Vb CDR3 is also similar to VH CDR3 in being
encoded by D and J gene segments. The extra hypervari-
able region of Vb (HV4) is intermediate in length
between the corresponding VL and VH loops; it tucks in
close to CDR1 and CDR2, more like the analogous region
in VL (see Fig. 1).
The Va domain closely resembles Vb (see Fig. 2) and is
also more similar to a VL than a VH domain. In Va,
however, the bilayer b-sheet structure is slightly modified
relative to Vb, VL and VH: a b strand from one sheet is
switched over to the other b sheet. The Va CDR1 is on
average shorter than the VL CDR1, ranging from ten to
thirteen amino acids in length [17]; the CDR2s are more
variable in length and conformation. The Va CDR3 also
shows length variation, ranging from nine to fifteen
residues [17]. In the isolated Va structure [5] the CDR3
was disordered; in the complexes, however, the CDR3
loops were visible.
Turning to the constant regions, the T-cell receptor Cb
domain also closely resembles its immunoglobulin counter-
parts, though Cb is differentiated by a large, solvent-
exposed bulge. The bulge is produced by a thirteen or
fourteen residue insert in the loop region connecting the
last two b strands of the domain. The bulges in the two
murine b chains, 2C [6] and 14.3.d [8], have different loop
conformations, suggestive of flexibility in this region of the
molecule. The Ca domain appears to be highly deformable.
In the 2C structure, the Ca domain is characterized by high
thermal factors, indicative of relatively high mobility; in the
structure of the A6 T-cell receptor [7], the Ca domain is so
disordered that it was left out of the refinement. 
Although the 2C Ca domain has the basic immunoglobu-
lin fold [18], there are large departures from a typical
immunoglobulin C-type fold. The b sheet that interacts
with the opposite (Cb) domain is typical for a constant
domain, but the other b sheet is very different, with the b
strands too far apart to form the usual hydrogen-bonding
pattern of an antiparallel b sheet. The looser assembly of
the Ca b sheet structure results in greater exposure to
solvent of the interior hydrophobic residues. In Ca, the
conserved tryptophan residue, which occurs 14 residues
from the first cysteine of the intradomain disulfide bond
in Vb domains, is absent.
Structure of the complexes
Of greatest interest to immunologists, of course, is the
nature of the interface between the T-cell receptor and
the peptide–MHC complex, as we believe this should not
only reveal how a given T-cell receptor discriminates
between self and antigenic peptide–MHC complexes but
also should shed light on the enigmatic phenomenon of
antagonist peptides — peptides structurally similar to anti-
genic ones, but capable of delivering qualitatively distinct
signals to the T cell. We now have structures of two T-cell
receptor–peptide–MHC complexes: those of the receptor
2C bound to a complex between the murine MHC mole-
cule H-2Kb and peptide dEV8 [6], determined at modest
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Figure 3
A comparison of the sites of interaction with
their peptide–MHC ligands of the 2C [6] (a)
and A6 [7] (b) T-cell receptors. (a) Shows the
‘footprint’ of the 2C binding site on the
peptide–H-2Kb molecular surface.
(Reproduced with permission from [6].) (b)
Shows the ‘footprint’ of the A6 T-cell receptor
on the peptide–HLA-A2 molecular surface.
(Reproduced with permission from [7].)
resolution with no refinement, and of receptor A6 bound
to a complex between the human MHC molecule HLA-
A2 and peptide Tax [7], determined at high resolution
with a reliable structure for the domains involved in the
interface.
As illustrated in Figure 2, the dimensions of the T-cell
receptor and its relative orientation to its ligand clearly
indicate that the CDRs make the primary binding interac-
tions with the peptide–MHC complex. The T-cell recep-
tor looks like an antibody Fab, and the interface with the
peptide–MHC complex is of similar dimensions to that
between antibodies and protein antigens [19]. The
detailed orientation of Va over the amino-terminal half of
the peptide and the ‘left-hand’ side of the a1 and a2
helices of the MHC molecule, and the way Vb shadows
the carboxyl-terminal half of the peptide and the ‘right-
hand’ side of the a1 and a2 helices, are the same for both
T-cell receptor–peptide–MHC complexes [6,7], and
strong arguments can be made [7] that this will be a
canonical orientation for all ab T-cell receptor–MHC
interactions.
Scrutiny of the regions of the peptide–MHC complex
that are contacted by the CDRs and HV4 of Va and Vb
(Fig. 3) supports some predictions of the range of varia-
tion that different T-cell receptor–peptide–MHC com-
plexes may encompass. Whereas the 2C T-cell receptor
[6] interacts directly with the centre of the bound peptide
in its peptide–H-2Kb ligand through a relatively small
area of its Va and Vb CDR3s, the A6 T-cell receptor [7]
exploits an extensive area of contact between Vb CDR3
and its peptide–HLA-A2 ligand, with relatively little con-
tribution from Vb CDR2 and none from Vb CDR1. The
three Va CDRs of the A6 receptor make roughly equal
contacts with the peptide–HLA-A2 complex. In the
structure of the A6 complex, the Tax peptide was found
to be embedded more deeply inside the HLA-A2 binding
groove than in the isolated peptide–MHC complex, pro-
viding evidence for an ‘induced fit’ mechanism of recep-
tor binding [7].
Our knowledge of the scope of T-cell receptor interac-
tions is further increased by the structure of the b chain
complexed with a bacterial superantigen [8]. A full
picture of the receptor–superantigen interaction will
require determination of a structure that includes the a
chain. Nevertheless, the structure has allowed Fields et
al. [8] to propose a model that accounts for the ability of
superantigens to bind b chains alone, for the MHC-
dependence of the presentation of the low-affinity
superantigens to T cells, and for the Vb-family restric-
tion of some superantigens. The relatively weak interac-
tion of the superantigen with Vb CDR3 in this complex
explains the lack of influence of particular peptides in
the peptide–MHC complex on superantigen specificity.
A glimpse ahead
The new T-cell receptor structures have enhanced our
knowledge of the kinds of interactions in which immuno-
logical cell-surface receptors can participate, and augur well
for future studies. Questions of the dynamic nature of the
surface events in T-cell activation remain, but we can feel
confident that with the contemporary cooperation of molec-
ular expression systems and X-ray crystallography the
details of the static structure of ever more extensive T- cell
activation complexes, in which the ab T-cell receptor, CD3
signalling complex, peptide–MHC ligand, coreceptor, and
accessory and costimulatory molecules will be visualized.
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